BioMotiv, a drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (BMS), have launched Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases. The intellectual property behind Anteros was first developed by Yale University and in-licensed by BMS and subse...